Urine RNA Test Has Outperformed Standard Cancer Screenings
A new diagnostic tool may help predict how patients respond to common bladder cancer immunotherapy treatments.
Updated on Oct. 13, 2026 in Cancer
Live Poll
Would you trust a non-invasive urine test over a surgical procedure for cancer monitoring?
Researchers developed a noninvasive urine cell-free RNA test that showed significantly higher sensitivity for detecting bladder cancer compared to standard urine cytology. This tool also demonstrated the capability to identify which patients are likely to respond to Bacillus Calmette-Guérin immunotherapy.
Why it matters
Bladder cancer monitoring currently relies on invasive cystoscopy procedures, but this test offers a noninvasive alternative to track disease and guide clinical decisions. By predicting response to standard immunotherapies, it could eventually help doctors tailor care to the specific biological markers of an individual's tumor.
In a study published in Nature Medicine involving 515 individuals and 683 urine samples, the cfRNA test achieved 96% sensitivity in one cohort of 93 patients and 99% in another of 85, compared to 34% for cytology and 85% for DNA-based testing. These findings remain preliminary pending further prospective validation.
The players
Stanford University
An academic institution where the researchers led the study on bladder cancer diagnostics.
Palo Alto VA
A healthcare facility that served as an enrollment site for the study participants.
The details
The test analyzes fragmented RNA found in urine to profile gene expression linked to cancer activity. A trained model processes these RNA signals, identifying specific T-cell immune signals and tumor cell proliferation markers to determine if a tumor is high-grade or low-grade. This molecular profiling allows the test to distinguish between patients who will effectively respond to Bacillus Calmette-Guérin immunotherapy and those who may not.
Timeline
October 2026: Study findings published in Nature Medicine.
Health Landscape
This development addresses a critical gap in the management of bladder cancer by providing a molecular alternative to traditional diagnostic methods. It aligns with ongoing efforts to optimize the use of Bacillus Calmette-Guérin immunotherapy by identifying biological signals of treatment efficacy.
Patients currently monitoring bladder cancer should talk with their urologist about the status of noninvasive liquid biopsy tests. While this specific method is currently undergoing study, it highlights the importance of asking about new diagnostic options beyond traditional invasive cystoscopies.
The takeaway
This urine-based test represents a significant potential advancement in personalizing bladder cancer treatment. If you are undergoing care for bladder cancer, continue to follow your physician's schedule for cystoscopy while discussing emerging noninvasive screening technologies that may become available.
Further reading
For more information on the latest innovations in screening and detection, visit Cancer.
Live Poll
Would you trust a non-invasive urine test over a surgical procedure for cancer monitoring?
